CDS2 (CDP-diacylglycerol synthase 2) catalyzes the conversion of phosphatidic acid to CDP-diacylglycerol (CDP-DAG), a critical intermediate in phospholipid synthesis 1. The enzyme exhibits specificity for particular acyl chain compositions, preferring 1-stearoyl-2-arachidonoyl substrates 1. CDS2 plays important roles in regulating lipid droplet growth and maturation, which are central to lipid and energy homeostasis 23. CDS2 functions at the endoplasmic reticulum, where it catalyzes a rate-limiting step in phosphatidylinositol (PI) synthesis 4. Clinically, CDS2 represents a synthetic lethal vulnerability in cancers with low CDS1 expression, including uveal melanoma, mesenchymal-like cancers, and pancreatic ductal adenocarcinoma 567. CDS2 knockout disrupts phosphoinositide synthesis, impairs lipid homeostasis, and triggers apoptosis in these cancer contexts 56. Additionally, CDS2 is implicated in diabetic wound healing through METTL3-mediated RNA methylation affecting mitochondrial function 8. The CDS1/CDS2 axis represents a promising therapeutic target across multiple cancer types, with CDS2 being pharmacologically tractable through inhibition of its catalytic activity 6.